- Born:
- 1956, New York City, New York (age 70)
- Awards And Honors:
- Nobel Prize (2019)
- Subjects Of Study:
- Down syndrome
- cancer
- erythropoietin
- hypoxia
- hypoxia-inducible factor
- tumour
Gregg L. Semenza
-
Who is Gregg L. Semenza?
Gregg L. Semenza, born in New York City in 1956, is an American physician and scientist celebrated for his research on how cells regulate and use oxygen. His most notable contribution is the discovery of hypoxia-inducible factor (HIF), a molecule activated by reduced oxygen levels in cells, crucial for cell survival in certain diseases.
Semenza's work has paved the way for new treatments for diseases like cancer and ischemic cardiovascular disease, where reduced oxygen availability is a key factor. In 2019, he shared the Nobel Prize for Physiology or Medicine with William G. Kaelin, Jr., and Sir Peter J. Ratcliffe for his discoveries regarding HIF.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is Gregg L. Semenza known for?
Gregg L. Semenza, born in New York City in 1956, is an American physician and scientist notable for his research on how cells utilize and regulate oxygen. His most famous contribution is the discovery of hypoxia-inducible factor (HIF), a molecule activated by reduced oxygen levels in cells. HIF plays a crucial role in enabling cells to survive in certain diseases. Semenza's work paved the way for new treatments for diseases like cancer and ischemic cardiovascular disease, where reduced oxygen availability is a major factor. He was awarded the 2019 Nobel Prize for Physiology or Medicine for his discoveries, sharing it with William G. Kaelin, Jr., and Sir Peter J. Ratcliffe.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What important discovery did Gregg L. Semenza make?
Gregg L. Semenza is an American physician and scientist notable for his research on how cells regulate and use oxygen. His most significant discovery is the hypoxia-inducible factor (HIF), a molecule activated by reduced oxygen levels in cells. HIF plays a critical role in enabling cells to survive in certain diseases.
Semenza observed that HIF levels increase significantly under hypoxia (low-oxygen conditions), while HIF expression decreases under normal oxygen conditions. His investigations into HIF's role in cancer revealed that elevated HIF expression allows tumor cells to thrive and proliferate in hypoxic conditions. He also investigated novel therapies for ischemic cardiovascular disease, characterized by reduced blood flow and oxygen delivery to the heart. Semenza's discovery of how cells sense and adapt to reduced oxygen levels was the basis for the 2019 Nobel Prize in Physiology or Medicine, which he shared with William G. Kaelin, Jr., and Sir Peter J. Ratcliffe.
3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How did his research help us understand how cells respond to low oxygen?
Gregg L. Semenza's research on cellular responses to varying oxygen levels led to his discovery of hypoxia-inducible factor (HIF). HIF dictates cellular responses to oxygen availability, particularly in hypoxic conditions, by increasing significantly under hypoxia and decreasing under normal oxygen conditions. His work demonstrated how cells adapt to reduced oxygen levels, which is crucial for understanding diseases like cancer and ischemic cardiovascular disease. In cancer, elevated HIF expression allows tumor cells to thrive in low-oxygen conditions. Semenza's discoveries opened doors for novel treatments for diseases related to reduced oxygen availability.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
Why is the discovery of how cells sense oxygen important in medicine?
Gregg L. Semenza's investigations into how cells sense oxygen led to the discovery of hypoxia-inducible factor (HIF). HIF is activated when cells have reduced oxygen and enables them to survive in certain diseases. Semenza's work is important in medicine because it paved the way for new treatments for diseases like cancer and ischemic cardiovascular disease, where reduced oxygen availability is a major issue. In cancer, elevated HIF expression allows tumor cells to grow even with low oxygen levels. The understanding of how cells adapt to reduced oxygen formed the basis of the 2019 Nobel Prize for Physiology or Medicine.
3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What major awards or recognition has Gregg L. Semenza received for his work?
Gregg L. Semenza is an American physician and scientist notable for his research on how cells use and regulate oxygen. His discovery of hypoxia-inducible factor (HIF) opened doors for novel treatments for diseases, such as cancer and ischemic cardiovascular disease.
Throughout his career, Semenza received multiple awards for his work. These include the 2010 Canada Gairdner International Award and the 2016 Albert Lasker Basic Medical Research Award (shared with William G. Kaelin, Jr., and Sir Peter J. Ratcliffe). In 2019, Semenza, Kaelin, and Ratcliffe jointly received the Nobel Prize for Physiology or Medicine. Semenza was also elected as a member of the National Academy of Sciences in 2008 and the National Academy of Medicine in 2012.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
Gregg L. Semenza (born 1956, New York City, New York) is an American physician and scientist known for his investigations of how cells use and regulate oxygen and for his discovery of hypoxia-inducible factor (HIF), a molecule that is activated by reduced oxygen availability in cells and that plays a critical role in enabling cells to survive in certain disease states. Semenza’s research opened a door for the investigation and development of novel treatments for diseases such as cancer and ischemic cardiovascular disease, in which reduced oxygen availability is a major feature of disease. For his discoveries he was awarded the 2019 Nobel Prize for Physiology or Medicine (shared with American scientist William G. Kaelin, Jr., and British scientist Sir Peter J. Ratcliffe).
Semenza attended Harvard University, where he studied pediatric genetics, focusing primarily on chromosomal alterations in Down syndrome, and earned a bachelor’s degree in 1978. He continued his education at the University of Pennsylvania, graduating in 1984 with medical and doctorate degrees. In 1986, having completed an internship and a residency in pediatrics at Duke University, Semenza pursued postdoctoral studies in medical genetics at Johns Hopkins University in Baltimore. He remained at Johns Hopkins for the duration of his career, joining the faculty in 1990 and establishing his own laboratory there. He later served as director of the Vascular Program at the Johns Hopkins Institute for Cell Engineering.
In the late 1980s Semenza became curious about the mechanisms underlying cellular responses to changes in oxygen availability. Although researchers understood that a hormone known as erythropoietin was produced by cells in response to hypoxia (low-oxygen conditions), virtually nothing was known about the genetic mechanisms controlling this response. Semenza’s search for genetic factors that control how cells react to low oxygen levels led him to discover HIF. He and colleagues found that HIF directs a wide array of cellular responses to oxygen availability and, in particular, dictates responses to hypoxic conditions. Semenza observed that HIF levels increase significantly under hypoxia, whereas HIF expression is decreased under normal oxygen conditions. He subsequently investigated the role of HIF in cancer, where elevated HIF expression enables tumour cells to thrive and proliferate under hypoxic conditions, and investigated novel therapies for ischemic cardiovascular disease, which is characterized by reduced blood flow, and hence reduced oxygen delivery, to the heart.
Semenza was recognized for his work with multiple awards throughout his career. He shared the 2010 Canada Gairdner International Award and the 2016 Albert Lasker Basic Medical Research Award with Kaelin and Ratcliffe. He was an elected member of the National Academy of Sciences (2008) and the National Academy of Medicine (2012).